Patents Examined by Theodore R West
  • Patent number: 10781189
    Abstract: The present invention relates to 1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: September 22, 2020
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • Patent number: 10780100
    Abstract: This application is directed to a homogeneous solution of an aqueous, topical composition useful for the treatment of infection and/or for the treatment of inflammation due to trauma to tissue. Specifically, this application relates to a homogeneous, aqueous composition of a quinolone antibiotic and an anti-inflammatory agent.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 22, 2020
    Inventor: Randal Davis
  • Patent number: 10772847
    Abstract: Provided herein are formulations that can be effective to kill a pancreatic cancer cell that can include fendiline and a MET inhibitor, an aurora-ABC inhibitor, or an autophagy inhibitor. Also provided herein are methods of treating pancreatic cancer or a symptom thereof in a subject in need thereof, where the method can include the step of administering fendiline and a MET inhibitor, an aurora-ABC inhibitor, or an autophagy inhibitor.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: September 15, 2020
    Inventor: Jaya Padmanabhan
  • Patent number: 10774288
    Abstract: Compositions which are fragrant and contain at least a member set culled from a library of compositions, each being comprised of sub-combinations of selected terpenes. Fragrances that mimic that of various states of organic and synthetic aromatics including products, processes and those from non-combusted plant products, among other things, uniquitous products, processes, medicinals, and related moieties leverage databases of all known terpene groupings are offered for consideration, and have been provided, according to the instant teachings.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: September 15, 2020
    Assignee: The Werc Shop, LLC
    Inventors: Sytze Elzinga, Jeffrey C. Raber
  • Patent number: 10772910
    Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, the pharmaceutical composition including a graphene nanostructure as an active ingredient.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: September 15, 2020
    Assignees: Seoul National University R&DB Foundation, The Johns Hopkins University
    Inventors: Byung Hee Hong, Je Min Yoo, Hanseok Ko, Donghoon Kim
  • Patent number: 10765646
    Abstract: Methods of treating developmental encephalopathies by administering compositions including ketamine, norketamine, or other derivatives of ketamine, or a pharmaceutically acceptable salt of any of the foregoing, are provided. The methods and compositions may be used to treat conditions such as Dravet syndrome.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: September 8, 2020
    Inventor: Matthew During
  • Patent number: 10758547
    Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: September 1, 2020
    Assignee: Shimoda Biotech (PTY) Ltd
    Inventor: Henk Swart
  • Patent number: 10759807
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 1, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Patent number: 10758554
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: September 1, 2020
    Inventors: Yoko Endo, Kyohei Takahashi, Shinya Umezaki
  • Patent number: 10751318
    Abstract: The current invention relates to a co-crystal of carboplatin with 1,2-cis-cyclobutane dicarboxylate and its pharmaceutical use. The co-crystal of the current invention can be used in the treatment and/or prevention of cancer, as well as the treatment and/or prevention of a virus infection.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: August 25, 2020
    Inventor: Xiaozhong Liu
  • Patent number: 10736877
    Abstract: The present disclosure provides compositions that inhibit the SH2-containing inositol 5?-phosphatase (SHIP), as well as methods using such compositions for use in treating or ameliorating the effects of a medical condition in a subject.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: August 11, 2020
    Inventors: William G. Kerr, Sandra Fernandes Denney, John D. Chisholm
  • Patent number: 10729677
    Abstract: The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: August 4, 2020
    Inventor: Robert Vink
  • Patent number: 10729632
    Abstract: A sweetener composition comprising: at least one sweetener; at least one anti-foaming agent; and at least one flavour enhancer, wherein the flavour enhancer is: at least one high potency sweetener that contains hydrophilic and hydrophobic structural moieties; and used in an amount below its sweetness threshold.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: August 4, 2020
    Assignee: Tate & Lyle Ingredients Americas LLC
    Inventors: Joshua Nehemiah Fletcher, Jason C. Cohen, Adrienne Stucky Pohrte
  • Patent number: 10729697
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: August 4, 2020
    Inventor: Herriot Tabuteau
  • Patent number: 10722517
    Abstract: In certain embodiments the present invention provides methods useful in the treatment of glioma, such as glioblastoma, such methods comprising administering to a subject in need thereof a CSF-IR inhibitor together with one or more additional active agents such as IGF-IR inhibitors, PI3K inhibitors, IL4 inhibitors, NFAT inhibitors, and/or Stat6 inhibitors. In certain embodiments the present invention provides pharmaceutical compositions comprising a CSF-IR inhibitor together with one or more of such additional active agents.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: July 28, 2020
    Inventors: Daniela Francis Quail, Johanna Alexandra Joyce, Robert Lyle Bowman
  • Patent number: 10723744
    Abstract: Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 28, 2020
    Inventors: Jonathan Steven Alexander, April C. Carpenter, Trevor Percival Castor
  • Patent number: 10725042
    Abstract: A method of determining the susceptibility of a cancer in a subject to treatment with an antimetabolite includes obtaining a sample of cancer cells from the subject, measuring the level of UDG expression in the cancer cells, and comparing the measured levels of UDG expression in the cancer cells to a control level.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: July 28, 2020
    Inventor: Stanton Gerson
  • Patent number: 10709685
    Abstract: Disclosed are methods of treating anxiety or depression, comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP), 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: July 14, 2020
    Assignee: Georgetown University
    Inventors: Kenneth J. Kellar, Yingxian Xiao, Patrick A. Forcelli
  • Patent number: 10709680
    Abstract: This invention relates to methods for improving the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: July 14, 2020
    Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
  • Patent number: 10702510
    Abstract: Disclosed herein are methods of reducing muscle contraction in a diaphragm or peripheral muscle(s) of a patient sufficient to permit a surgical procedure. The methods may comprise the step of administering an oxime or pharmaceutically acceptable salt thereof to a subject in need thereof in an amount sufficient to achieve said reduced muscle contraction/neuromuscular blockade. Kits and articles of manufacture comprising a container having a label and a composition are also disclosed.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: July 7, 2020
    Assignee: Battelle Memorial Institute
    Inventors: Brian L. Burback, Jessica Catherine Bright, Jerry D. Johnson